Evaluations of the activities of floxacrine [7-chloro-10-hydroxy-3-(4-trifluoromethylphenyl)-3,4-dihydroacridine-1,9(2H, 10H)-dione] in owl monkeys infected with trophozoites of a chloroquine-quinine-resistant strain of Plasmodium falciparum, a strain of this plasmodium resistant to both of these quinolines and pyrnmethamine, or a strain of P. vivax resistant only to pyrimethamine showed that: (i) this compound regularly effected temporary clearance of parasitemia at daily doses of 1.25 to 2.5 mg/kg; (ii) doses required for the cure of established infections were larger by factors of 6 to 64 than those that effected parasite clearance; (iii) there was more than a 10-fold difference in doses required for the cure of infections with the different strains; and (iv) resistance to floxacrine developed rapidly. Evaluations of the activities of floxacrine in rhesus monkeys challenged with sporozoites of P. cynomolgi showed that: (i) 0.625-mg/kg doses administered daily throughout the incubation period provided complete protection against infection; (ii) single 40.0-mg/kg doses delivered 2 h before sporozoite challenge were without prophylactic activity; and (iii) daily doses of 40.0 mg/kg, the maximum tolerated level, productive of a hemorrhagic syndrome in some subjects, would not cure established infections. These observations suggest that the potential contribution of floxacrine to malaria therapy would be limited to the prophylactic area and for practical reasons would be restricted there by the requirement for daily dosage.
Investigations by Raether identical doses of this dihydroacridinedione derivative were required for the cure of infections with the drug-susceptible strain and strains resistadnt to chloroquine, pyrimethamine, and sulfadoxine; (iii) floxacrine was approximately twice as active when administered subcutaneously as when delivered orally; and (iv) irrespective of route of administration, the compound had a favorable therapeutic index; i.e., the ratio of the 50% lethal dose to the dose required to cure 50% of infections (LD5o/CD5o) was in excess of 30. Studies by Fink showed that a single 1.0-mg/kg dose, administered intraperitoneally 24 h before intravenous challenge with sporozoites of 476 SCHMIDT olgi indicated that in this model the blood schizonticidal activity of floxacrine approximated that of chloroquine.
The above observations suggested that floxacrine might have potentials both for treatment of active infections with drug-susceptible and drug-resistant strains of the human plasmodia and for prophylaxis or radical cure of naturally acquired P. vivax infections. Further explorations of these potentials were undertaken in our laboratories. The first was examined in owl monkeys infected with trophozoites of a chloroquinequinine-resistant, pyrimethamine-susceptible strain of P. falciparum, a multidrug-resistant strain of this plasmodium, or a pyrimethamineresistant, chloroquine-susceptible strain of P. vivax. The second was evaluated in rhesus monkeys either challenged or actively infected with sporozoites of the B strain of P. cynomolgi. The dimensions and results of these explorations have been summarized in this report.
MATERIALS AND METHODS
Procedures pertinent to evaluations of the activities of floxacrine against infections with P. falciparum and P. vivax in owl monkeys. The chloroquine-quinine -resistant, pyrimethamine -susceptible Vietnam Oak Knoll and chloroquine-quininepyrimethamine-resistant Vietnam Smith strains of P. falciparum, and the chloroquine-quinine-susceptible, pyrimethamine-resistant Vietnam Palo Alto strain of P. vivax were used in this study. The patient origins of these strains, the procedures employed in adapting them to growth in owl monkeys with intact spleens and maintaining them at constant virulence, the courses of infections in untreated monkeys, and the responses of standardized infections to treatment with chloroquine, quinine, and pyrimethamine have been described elsewhere (5) (6) (7) .
A total of 44 owl monkeys (Aotus trivirgatus griseimembra) imported directly from Barranquilla, Colombia, was used in the current experiments. This group included approximately equal numbers of subadult or adult males and females, ranging from 700 to 1,040 g in weight at the time of assignment to specific studies. The procedures followed in importing these monkeys, adapting them to a caged environment and laboratory diet, maintaining them in a healthy state, and handling them during conditioning and experimental study periods were identical with those detailed previously (5, 6) .
Of the 44 monkeys, 25 with no previous malaria experience were used to evaluate the activities of floxacrine against infections with the Oak Knoll and Smith strains of P. falciparum. This subgroup included 22 treated subjects and 3 untreated controls. The remaining 19 monkeys, all previously infected with the Oak Knoll strain of P. falciparum and cured via treatment with a 4-quinolinemethanol or 4-pyridinemethanol (11, 13) , were used for studies with the Palo Alto strain of P. vivax. Fifteen of the 19 (14 treated and 1 untreated control) were employed in the primary ANTIMICROB. AGENTS CHEMOTHER. assessment of the activity of floxacrine. Four (three treated and one untreated) were used in determining whether resistance to this compound was responsible for treatment failures encountered in the primary evaluation.
The blood schizonticidal activities of floxacrine were evaluated by procedures essentially identical to those detailed previously (8) . In brief, infections were induced by intravenous inoculation of 5 x 106 erythrocytic parasites derived from monkeys in the passage lines of the respective strains. Measurements of parasitemia on thick and thin blood films, prepared from the marginal ear vein and stained with Giemsa, were initiated 3 days after inoculation and were repeated daily thereafter until densities of 10 If parasitemias persisted at the initial or lower levels or increased during the delivery of floxacrine, or if parasites reappeared after an apparent blood-negative interval, a second treatment course was initiated, almost invariably at a dose twofold to fourfold larger than that administered during the initial course. This procedure was repeated until the infection was cured or a dose level of 80.0 mg/kg had been reached without effecting cure. This retreatment practice not only expands information that can be obtained via study on a single monkey, but as shown in this report and others (5, 8) , may also signal the emergence of parasites resistant to the compound under investigation.
As detailed elsewhere (7), responses to treatment were classified as: (i) none, when the course of the parasitemia in the treated subject was essentially the same as in the untreated controls or fell within the boundaries of historical controls infected with the same strain; (ii) suppressed, when parasitemia persisted throughout the treatment period, but was either less than at the start of treatment or no greater than 1/50 the levels in untreated controls; (iii) clearance with recrudescence, when thick blood films became parasite negative during the latter days of treatment or immediately thereafter and remained so for a minimum of 7 days before reestablishment of parasitemia; and (iv) cured, when thick films became parasite negative during or immediately after treatment and remained so during a follow-up period of 90 days or longer.
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Procedures pertinent to evaluations of the prophylactic and radical curative activities of floxacrine in rhesus monkeys inoculated with sporozoites of P. cynomolgi. The B strain of P. cynomolgi was used in these studies. Reference should be made to earlier reports (10, (18) (19) (20) for detailed descriptions of: (i) the origin of this strain and its routine maintenance in this laboratory; (ii) procedures employed in obtaining batches of infected Anopheles freeborni and preparing, measuring, and delivenng sporozoite inocula; (iii) methods used for routine detection and quantification of parasitemias; (iv) characteristics of untreated sporozoite-induced infections; (v) responses of established infections to standard blood schizonticidal and tissue schizonticidal drugs; and (vi) procedures employed in assessing prophylactic and radical curative activities of new agents.
A group of 48 subadult rhesus monkeys (Macaca mulatta), imported directly from New Delhi, India, and conditioned in our animal quarters, was used in the current study. All monkeys were tuberculin negative upon receipt and, as judged by results of routine monthly tests for tuberculin skin hypersensitivity, remained so throughout residence in the colony. Of the above subjects, 42 without previous malaria experience were used in evaluating the prophylactic and radical curative activities of floxacrine. This subgroup included 24 males and 18 females, ranging from 3.7 to 5.0 kg in weight at the time of assignment to an experiment. Another four monkeys, infected with trophozoites of the B strain for other purposes, were used for a preliminary appraisal of the blood schizonticidal activities of floxacrine, an evaluation required to guide the dosage regimen employed in assessing radical curative activity. Finally, two monkeys, discarded as cured from an unrelated malaria therapy experiment, were used in a preliminary study of the capacity of floxacrine to produce hypoprothrombinemia. The reason for and scope of this study are detailed in the Results section.
The prophylactic activity of floxacrine was evaluated in four experiments. In three, involving 19 The evaluation of the radical curative activity of floxacrine, carried out with well-established procedures (18, 20) , involved work with 17 monkeys. Eleven were infected specifically for this appraisal, receiving inocula ranging from 1.0 x 106 to 3.0 x 106 sporozoites. The six remaining monkeys were derived from various prophylactic experiments where they had received doses of floxacrine that were without effect on the incubation period or subsequent evolution of parasitemia. Floxacrine was administered once daily for 7 consecutive days in all assessments of radical curative activity. When doses of 2.5 mg/kg or lower were employed, chloroquine was administered concomitantly at a daily dose of 2.5 mg of base per kg of body weight. This combination regimen was used to ensure eradication of blood schizonts, for as the results of the preliminary study referred to earlier showed, daily doses of 5.0 mg of floxacrine per kg were required for the cure of trophozoite-induced infections. Doses of 5.0 mg/kg or greater were administered alone; however, when parasitemia reappeared, infections were retreated with chloroquine, at 5.0 mg of base per kg daily for 7 days. This retreatment procedure is a routine for discriminating between recrudescence due to persistence of small numbers of blood schizonts and relapse due to continued multiplication of tissue schizonts (18, 20) . Parasitemias were monitored on Giemsa-stained thick and thin blood films prepared on alternate days throughout the evaluation of curative activity.
Administration of floxacrine and chloroquine.
A single lot of floxacrine [HOE-991, S 72 8991 (17 346/ 3)] was used in the experiments presented in this report. This compound, which is relatively water insoluble, was always administered orally. The quantity of agent required for treating a group of owl or rhesus monkeys was placed in a glass mortar, ground to a paste with 1/10 its weight of Tween 80, and then ground to a fine, relatively stable suspension with successive additions of distilled water until the appropriate concentration of floxacrine was attained. The volumes of suspension required for individual animals were transferred to Erlenmeyer flasks and diluted to a final volume of 10.0 ml for owl monkeys and 30.0 ml for rhesus monkeys. The contents of each flask were delivered to the appropriate subject by stomach tube, followed by a 3.0-ml distilled-water rinse of vessel and tube for an owl monkey and a 20.0-ml rinse for a rhesus monkey. Suspensions were made up fresh daily and administered within 1 h of preparation.
parasite development and cure infections in owl monkeys inoculated with blood schizonts of the Smith and Oak Knoll strains of P. fakciparum and the Palo Alto strain of P. vivax have been summarized in Table 1 . Utilizing the data in columns 2 to 6 of this summary, the total-course doses of floxacrine (seven times the daily doses) required for cure of 50 and 90% of established infections have been calculated (4) , wherever results permitted, and are set forth as CD,o's and CDso's in Table 2 .
The data in Table 1 Treatment of the fifth recrudescence with 80.0-mg/kg doses not only failed to effect parasite clearance, but considering the immunity which Atr 7994 should have acquired during previous parasitic episodes, was probably without effect on parasite development. This failure to respond to a dose of floxacrine at least 32-fold greater than that which effected clearance of parasitemia in previously untreated infections could be interpreted as the result of the emergence of resistant parasites or, alternatively, induction of enzymes which converted floxacrine from an active antimalarial agent to an inactive metabolite. The acute shortage of previously uninfected monkeys precluded examination of the first alternative via direct experiments with the "Atr 7994R5 parasites." The magnitude of problems related to the isolation and chemical and biological characterization of floxacrine metabolites discouraged exploration of the second alternative.
The above alternatives were resolved via studies on Atr 7879, the treatment failure among the monkeys infected with the Palo Alto strain of P. vivax, and on its subinoculees. Initial treatment of Atr 7879 with floxacrine at daily doses of 40.0 mg/kg and the fit retreatment with 80.0-mg/ kg doses effected prompt although temporary clearance of parasitemia (Table 3) . Two additional treatment courses, each at a dosage of 80.0 mg/kg, were without significant effects on parasite numbers or morphology. To delineate the role of the parasite in this failure, each of a group of four previously used owl monkeys was inoculated with 5 x 106 trophozoites obtained from Atr 7879 just before delivery of the fourth treatment course. Administration of floxacrine in doses of 20.0, 40.0, or 80.0 mg/kg was without effect on the parasitemias of these subinoculees (Table 3 ). This result strongly supports the conclusion that emergence of parasites resistant to this compound was responsible for the treatment failure in Atr 7879. The failure encountered in Atr 7994 probably had a similar basis.
Prophylactic and radical curative activities of floxacrine in rhesus monkeys inoculated with sporozoites of P. cynomolgiL Floxacrine exhibited significant prophylactic activity (Table 4) . Doses of 0.625 mg/kg or greater administered on the day before challenge, 2 h before challenge, and daily thereafter throughout the 7-day incubation period provided complete protection against infection with relatively massive numbers of sporozoites. A dosage of 0.156 mg/kg completely protected two of four recipients and led to 3-and 6-day delays in the onset of parasitemia in the remaining two. Dosages of 0.039 and 0.0098 mg/kg were neither The capacity of floxacrine to effect radical cure of established sporozoite-induced infections was examined in two studies. In one, the compound was delivered over a dosage range of 0.0098 to 2.5 mg/kg, daily for 7 days, in combination with 2.5-mg/kg doses of chloroquine. In the second, it was administered over a dosage range of 5.0 to 40.0 mg/kg daily for 7 days, followed by dosage with chloroquine at 5.0 mg/ kg daily for 7 days when parasitemia recurred. The results of these evaluations showed that, when administered at doses up to the maximum tolerated level, floxacrine exhibited no capacity to cure established sporozoite-induced infections and had no discernible effect on the viability of the established tissue schizonts of P. cynomolgi.
All 21 infections treated with floxacrine in doses of 0.0098 to 2.5 mg/kg, in combination with chloroquine, relapsed within 4 to 9 days of completion of the dosage regimen (Table 6 ). Such relapse intervals are encountered regularly when chloroquine is employed alone for control of parasitemia in primary attacks induced by heavy sporozoite inocula (15) . In keeping with the results of the preliminary appraisal of the activity of floxacrine against trophozoite-induced infections, this compound effected parasite clearance in all 17 recipients of doses of 5.0 to 40.0 mg/kg when administered alone; however, parasitemias reappeared 7 to 12 days after completion of treatment (Table 7 , columns 3 and 6). Retreatment of the recurring infections with chloroquine was followed in every instance by a relapse 5 to 16 days after delivery of the last dose of this drug (Table 7 , column 8). Such relapse intervals are encountered routinely when chloroquine is used in the treatment of second and third attacks (15) . Their occurrence in the current setting indicates that floxacrine is devoid of activity against the mature persisting tissue schizonts.
Untoward reaction of rhesus monkeys to floxacrine. Although the current investigation was not concerned directly with the toxicity of floxacrine, note should be taken of an unexpected, potentially serious side effect first encountered in a rhesus monkey assigned to the initial appraisal of prophylactic activity. One of three recipients of 40.0-mg/kg doses died approximately 24 h after dose 8 (Table 4) . No untoward reactions were recognized at delivery of that dose, but 18 h later the animal was in shock and exhibited purpuric lesions over the ventral aspect of the chest, upper abdomen, axillae, and contiguous areas of the upper ann. Necropsy, performed within 30 min of death, revealed massive subcutaneous hemorrhage at these sites and, in addition, extensive hemorrhage in the mediastinum, omentum, and connective tissue about the kidneys, ureters, and uterus. Spilled blood failed to clot during the 60 min covered by the necropsy.
Since the dose partner of the monkey described above showed no untoward reactions, the syndrome was considered to be non-drug related, and a third monkey was inoculated with sporozoites and treated with 40.0-mg/kg doses of floxacrine as a replacement for the subject that died. On day 6 postchallenge, at delivery of dose 8, this replacement exhibited diffusely distributed petechiae over the face and thighs, and purpuric lesions over the chest and biceps. Relatively complete hematological and biochemical (Table 7) and again was con- "Dose of floxacrine indicated was administered once daily for 7 days concomitantly with chloroquine at 2.5 mg of base per kg of body weight.
b Letters in parentheses refer to attack treated: P, primary; R,, first relapse.
trolled by a dosage regimen of menadiol identical with that described above.
These observations led to a limited study of the effects of floxacrine on prothrombin time in a setting uncomplicated by recent introduction of mosquito tissue; as test subjects two exceptionally healthy rhesus monkeys, discarded approximately 4 months earlier as cured of their malarial infections, were used. Floxacrine was administered to each subject at a dose of 40.0 mg/kg once daily for 9 days. Complete blood counts and measurements of prothrombin time and glucose-oxalacetic acid-transaminase activity in serum were made daily beginning 4 (iii) Floxacrine was devoid of the capacity to cure established infections. The maximum tolerated daily dose (40.0 mg/kg), which produced a hemorrhagic syndrome in three of five recipients, effected clearance of blood schizonts, but neither prevented nor delayed relapse.
The divergence between the capacities of floxacrine to prevent and cure infections, referred to in i and iii above, merits special attention. Such a separation of prophylactic and radical curative properties has not been encountered before, either in studies in monkeys inoculated with sporozoites of various strains of P. cynomolgi (9, 15, 18, 20 ; L. H. Schmidt, unpublished data) or in human volunteers inoculated with sporozoites of the Chesson strain of P. vivax (personal communication, the late A. S. Alving, University of Chicago). In both systems, compounds that exhibited one activity exhibited both, with doses required for prevention either the same or slightly larger than those required for radical cure. Whereas the separation of such activities encountered with floxacrine is unique, it is not an unreasonable finding. There are major differences between the morphology of the developing tissue schizonts and the morphology of fully mature tissue schizonts and persisting tissue stages associated with relapse (1) (2) (3) . It would be remarkable if all classes of chemotherapeutic agents were equally active against forms of such structural diversity.
The failure of floxacrine to fully protect against infections with P. cynomolgi when administered in a single 40.0-mg/kg dose 2 h before sporozoite challenge is also noteworthy. Assuming that floxacrine has a half-life of 20 h (H. Wagner, personal communication), such a dose should have provided residues in excess of those equivalent to doses of 0.625 mg/kg for 5 days, 0.325 mg/kg for 6 days, and 0.156 mg/kg for 7 days. Failure to obtain full protection with such dosage coverage is perplexing. It raises a question as to whether what was measured in the phannacokinetic studies was floxacrine or a mix of that compound with inactive metabolites.
Since the studies recorded in this report were stimulated by the observations of Raether in mice infected with trophozoites of P. berghei and those of Fink in mice challenged with sporozoites of P. berghei yoelii, it is pertinent to examine the areas of agreement and disagreement in the results of these two groups of investigations. They are in agreement with respect to the finding that the capacity of floxacrine to effect temporary clearance of parasitemia is not prejudiced by resistance to chloroquine or pyrimethamine. They are also in harmony with respect to the prophylactic activity of floxacrine. The relations between the temporarily suppressive and curative doses of floxacrine and the relative activities of this compound and chloroquine differed significantly in the rodent and human plasmodium models. Whereas the data of Raether in infections with P. berghei indicated that there was no more than a twofold spread between the doses required for temporary clearance of parasitemia in 90% of the mice and the CD5o, observations in owl monkeys in-VOL. 16, 1979 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from ANTIMICROB. AGENTS CHEMOTHER. fected with human plasmodia showed that there was a 6-fold to 64-fold spread between doses required to effect clearance of parasitemia regularly and the CDso. Likewise, floxacrine was two to three times more active than chloroquine against infections with P. berghei. In contrast the activity of floxacrine was less than 1/40 that of chloroquine in infections with the chloroquine-susceptible Palo Alto strain of P. vivax in owl monkeys (7) . No comparison could be made of such highly important drug parameters as strain susceptibility and radical curative activity.
The former was not examined in the rodent model, whereas the latter could not be studied because of the absence of persisting tissue stages in infections with P. berghei yoelii.
Inasmuch as the current studies were designed to appraise the potential of floxacrine in the treatment of the human malarias, it is appropriate that this subject be touched on before concluding this report. The performance of floxacrine in owl monkeys infected with P. falci--parum or P. vivax indicates that this compound has significant shortcomings as a blocd schizonticide. First, the range of doses required for cure of established infections with various strains is large. To be broadly useful, especially when administrative control of drug application is mirnimal, any treatment regimen has to cover infections with strains of the least susceptibility.
Routine use of sizeable doses of floxacrine required to cover all contingencies might well evoke toxic reactions. Second, resistance to floxacrine emerges rapidly, at a rate not less than that of proguanil or pyrimethamine (16, 17) , compounds that have presented resistance problems in field use. Third, by comparison, floxacrine is a weak competitor of a group of aminoalcohols which have been studied in depth in the same animal models (11) (12) (13) (14) . Some have already exhibited promise in limited clinical trials (11, 12) . These compounds are from two to three times as active as chloroquine against infections with chloroquine-susceptible strains, are equally active against drug-susceptible and multidrugresistant strains, are effective in single-dose regimens, and, to this point, have not been associated with evolution of resistance. The performance of floxacrine in rhesus monkeys inoculated with sporozoites of P. cynomolgi has shown that this compound also has shortcomings as a tissue schizonticide. First, it appears to be totally lacking in radical curative activity. Secondly, although floxacrine has significant prophylactic activity, the requirement for daily dosage, if immutable, will be a serious handicap to general use. This is unfortunate, since dose for dose, this compound is slightly more active than primaquine as a prophylactic and much superior based on comparative therapeutic indexes (9, 18, 20) . All qualities considered, it seems unlikely that floxacrine could attain more than a limited role in malaria therapy. This pessimistic assessment of its utility could be tempered by the results of further studies.
